Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers by Alena Welters et al.
RESEARCH Open Access
Long-term medical treatment in congenital
hyperinsulinism: a descriptive analysis in a
large cohort of patients from different
clinical centers
Alena Welters1*, Christian Lerch2,3, Sebastian Kummer1, Jan Marquard1, Burak Salgin1,4,5, Ertan Mayatepek1
and Thomas Meissner1
Abstract
Background: Up to now, only limited data on long-term medical treatment in congenital hyperinsulinism (CHI) is
available. Moreover, most of the drugs used in CHI are therefore not approved. We aimed to assemble more objective
information on medical treatment in CHI with regard to type and duration, dosage as well as side effects.
Methods: We searched MEDLINE (from 1947) and EMBASE (from 1988) using the OVID interface for relevant data to
evaluate medical treatment in a large cohort of patients with CHI from different clinical centers. Randomized, controlled
trials were not available. We evaluated case reports and case series. No language restrictions were made.
Results: A total number of 619 patients were medically treated and information regarding conservative treatment was
available. Drugs used were diazoxide (in 84 % of patients), somatostatin analogues (16 %), calcium channel antagonists
(4 %) and glucagon (1 %). Mean dose of diazoxide was 12.5 (±4.3) mg/kg ⋅ d (range 2–60 mg/kg ⋅ d), mean duration of
diazoxide treatment until remission was 57 months. Side effects of diazoxide were usually not severe. The causal relation
between diazoxide and severe side effects, e.g. heart failure (3.7 %) remains doubtful. Mean dose of octreotide was 14.9
(±7.5) μg/kg ⋅ d (range 2.3–50 μg/kg ⋅ d), of lanreotide 67.3 (±39.8) mg ⋅ month (range 10–120 mg ⋅ month). Mean
duration of treatment with somatostatin analogues until remission was 49 months. Frequent side effects included
tachyphylaxis and mild gastrointestinal symptoms. The risk of persistent growth deceleration was low (<5 %).
Conclusions: Severe side effects are rare and a causal relation remains disputable. We conclude that long-term
conservative treatment of CHI is feasible.
Keywords: Congenital hyperinsulinism, Persistent hyperinsulinemic hypoglycemia of infancy, Diazoxide,
Octreotide, Lanreotide, Nifedipine, Glucagon
Background
Congenital hyperinsulinism (CHI) is a heterogeneous
disorder leading to increased, often unregulated secretion
of insulin from pancreatic beta cells. Clinical manifestation
ranges from life-threatening hypoglycemia in neonates to
mildly symptomatic hypoglycemia in early childhood,
adolescence or adulthood that might sometimes be
difficult to identify [1]. Up to now, mutations in nine
different genes have been identified. However, in almost
50 % of CHI-cases, the genetic mechanism is still un-
known, suggesting further disease-associated genes [2, 3].
CHI can be distinguished into a diffuse and focal type.
Focal CHI is defined as a focal adenomatous hyperplasia
of beta cells within the pancreatic tissue, which can be
identified by 18F-PET/CT and completely cured by surgi-
cal removal of the focal lesion [4, 5].
In contrast, in diffuse CHI hyperplastic insulin-secreting
beta cells are spread throughout the whole pancreas. Suffi-
cient reduction of hyperinsulinemia usually requires near
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total pancreatectomy, which in turn implicates the risk of
either persistent hypoglycemia or insulin-requiring dia-
betes [6, 7]. Therefore, long-term medical treatment was
established during the last decades for diffuse CHI. If CHI
is promptly diagnosed and adequately treated most of the
children develop a normal range of cognitive, emotional
and social skills. In these cases, clinical remission with
termination of all drugs may occur after several years of
intense conservative treatment [8, 9]. Common conserva-
tive long-term treatment options include the potassium
channel opener diazoxide (which is almost ineffective in
patients with defects of the KATP-channel), somatostatin
analogues (octreotide, lanreotide) or calcium-channel an-
tagonists [6, 9–11]. Although these drugs are frequently
used in patients with CHI, little is known about their dose,
efficacy and safety. Evidence-based guidelines to manage
recurrent hyperinsulinemic hypoglycemia do not exist and
therefore treatment strategies remain controversial. Im-
proved knowledge and optimization of conservative treat-
ment is thus of major importance, especially in diffuse
CHI, in which surgical cure cannot easily be achieved [7].
At present, treatment decisions are mostly based on
expert opinions obtained from single-center data.
This review aims to provide more objective informa-
tion collected from reports of more than 600 patients
from different clinical centers. Thereby, we provide an
overview of long-term conservative treatment in CHI
with regard to type and duration of treatment, dose and
frequency of severe as well as rare side effects that are
often difficult to assess in small patient cohorts and
single-center experiences.
Methods
We searched MEDLINE (from 1947) and EMBASE
(from 1988) using the OVID interface for relevant data.
Search terms were combined for the disease, specific
drugs and generic treatment options. Additional articles
were found by cross-reading reference lists of retrieved
articles. Efforts were made to translate non-english arti-
cles, which allowed us to include all relevant German,
Spanish, French, Portuguese, Turkish, Danish, Polish,
Chinese and Japanese articles. The latest article included
for evaluation was published in June 2013.
Results
In total 113 articles, mainly case reports and case series
were evaluated with specific regard to long-term conser-
vative treatment. The reviewed literature included a total
of 1261 patients with CHI, of which 718 patients received
long-term conservative treatment during their course of
disease. Long-term treatment was defined as minimum
duration of 6 months. Reports were also included if treat-
ment lasted for at least two months at the time of publica-
tion but was described as being ongoing.
For 50/718 patients a specific treatment regimen
was not necessary or not mentioned, another 49 pa-
tients were solely treated by frequent feedings and/or
specific diets. Finally, 619 patients were medically
treated and information regarding conservative treat-
ment was available. These patients are described sep-
arately. The medication most commonly used to
control hypoglycemia was diazoxide (84 %) followed
by somatostatin analogues (16 %), calcium channel an-
tagonists (4 %) and glucagon (1 %) (Table 1). For
evaluation of side effects, we included all patients that
did not meet our definition of long-term treatment. In
order to obtain as much information as possible on
very rare side effects, we furthermore discuss single
patients that experienced such side effects but were
treated with one of the studied medications because
of a disease other than CHI (e.g. octreotide in the
treatment of congenital chylothorax). These latter pa-
tients are clearly defined within the text and were not
included in the analysis resulting in table 2 (Table 2).
Dietary treatment
In 49 patients a “sufficient control” of hypoglycemia was
achieved with nutritional treatment. Importantly, the
definition of “sufficient control” might vary greatly
among the different hyperinsulinism centers further
stressing the necessity of establishing a standardized
fasting tolerance test to better compare the response to
dietary or medical treatment in between the different
clinical centers.
Almost half of these patients (49 %) were fed frequently
with glucose-enriched meals. Another eight patients
(16 %) additionally required raw cornstarch and also glu-
cocorticoids for a sufficient control of hypoglycemia [12].
Seventeen patients (35 %) were treated with a leucine-
restricted diet, of which all except two patients suffered
from the Hyperinsulinism-Hyperammonemia Syndrome
(HI/HA) caused by a mutation of the GLUD1 gene. The
other two patients treated with a leucine-restricted diet
were subsequently diagnosed as carrying a dominantly
inherited SUR1 mutation. Both of them developed mental
retardation due to recurrent seizures [13].
Discussion
The purpose of this study was to assemble information
on medical treatment of CHI with specific regard to type
and duration of treatment, dose, as well as side effects.
Since we collected as much information as available, in-
cluding case reports in various languages from different
clinical centers worldwide, the strength of the evidence
has to be critically assessed. Our results are biased by
the fact that publication practices tend to favor positive
treatment responses and that very rare or severe side
effects are more likely to be published. However, we
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believe that with a more rigorous approach with regard
to the quality of data, a lot of important information
would have been lost. The lack of objective information
on long-term medical treatment in CHI, in particular
with respect to the heterogeneity of the condition itself
is a general dilemma for the treatment of patients with
CHI and appropriate counseling of their parents. We are
therefore convinced that the careful recapitulation of
what has been reported for a large cohort of patients
might help to improve the knowledge and decisions on
long-term treatment of CHI even with respect to the
weakness that published data are biased and the lack of
a more critical approach to the evaluation of the reports.
Diazoxide
Diazoxide is a KATP-channel opener and the only drug ap-
proved by the Food and Drug Administration (FDA) for
long-term treatment of hyperinsulinemic hypoglycemia.
However, many patients are diazoxide resistant due to
mutations in the two genes encoding the KATP-channel of
the pancreatic beta cell (ABCC8/KCNJ11) [14] In total
521 patients were treated long-term with diazoxide, either
Table 1 Characteristics of long-term conservative treatment in CHI: detailed description of different treatment regimen with focus
on dose, combination of different drugs and duration of treatment. Patients receiving a combined therapy are listed twice
Drug Long-term treated Combined therapy Dose Course of treatment
DZX n total 521
n previous surgery 16 (3 %)
monotherapy
n = 380 (73 %)
combined therapy
n = 141 (27 %)
+ dieta n = 113 (79 %)
+ STA n = 9 (6 %)
+ CCA n = 2 (1 %)
>2 combinations
+ STA + dieta n = 15 (11 %)
+ CCA + dieta n = 2 (1 %)
n dose given 278 (53 %)
mean: 12.5 (±4.3) mg/kg • d
range: 2–60 mg/kg • d
2–3 single doses p.o. • d
n treatment ongoing 138 (26 %)
duration given for n = 113/138 (82 %)
mean duration: 62 months
n off medication 69 (13 %)
duration given for n = 56/69 (81 %)
mean duration: 57 months
n switched to other therapy 4 (1 %)
partial pancreatectomy: 3/4 (75 %)
STA: 1/4 (25 %)
n not mentioned; no follow-up 309 (59 %)
n dead 1 (0.2 %)
STA n total 100
OCT n = 79 (79 %)
LRT n = 21 (21 %)
n previous surgery 17 (17 %)
monotherapy
n = 54 (54 %)
combined therapy
n = 46 (46 %)
+ dieta n = 16 (35 %)
+ DZX n = 9 (20 %)
+ CCA n = 4 (9 %)
+ GLC n = 2 (4 %)
>2 combinations
+ DZX + dieta n = 15 (11 %)
OCT
n dose given 61 (77 %)
mean: 14.9 (±7.5) μg/kg • d
range: 2.3–50 μg/kg • d
continuously s.c. n = 28 (46 %)
3–6 injections s.c. • d n = 17 (28 %)
not specified n = 16 (26 %)
LRT
n dose given 11 (52 %)
mean: 67.3 (±39.8) mg • month
range: 10–120 mg • month
s.c. n = 8 (38 %)
i.m. n = 13 (62 %)
n treatment ongoing 39 (39 %)
duration given for n = 39/39 (100 %)
mean duration: 35 months
n off medication 22 (22 %)
duration given for n = 6/22 (27 %)
mean duration: 49 months
n switched to other therapy 10 (10 %)
partial pancreatectomy: 3/10 (30 %)
DZX: 3/10 (30 %)
gastrostomy feeding: 2/10 (20 %)
DZX + CCA: 1/10 (10 %)
megestrol acetate: 1/10 (10 %)
n not mentioned; no follow-up 29 (29 %)
CCA n total 25
NIF n = 19 (76 %)
VPM ° n = 2 (8 %)
AML n = 1 (4 %)
not specified n = 3 (12 %)
n previous surgery 10 (40 %)
monotherapy
n = 15 (60 %)
combined therapy
n = 10 (40 %)
+ dieta n = 2 (20 %)
+ DZX n = 2 (20 %)
+ STA n = 4 (40 %)
>2 combinations
+ DZX + dieta n = 2 (20 %)
NIF
n dose given 18 (95 %)
mean: 0.72 (±0.36) mg/kg • d
range: 0.1–2 mg/kg • d
VPM
n dose given 2 (100 %)
dose: 240 mg • d
AML
n dose given 1 (100 %)
dose: 0.1 mg/kg • d
2–4 single doses p.o. • d
n treatment ongoing 16 (64 %)
duration given for n = 16/16 (100 %)
mean duration: 25 months
n not mentioned; no follow-up 9 (36 %)
GLC n total 7
n previous surgery 6 (86 %)
monotherapy
n = 2 (29 %)
combined therapy
n = 5 (71 %)
+ dieta n = 3 (60 %)
+ STA n = 2 (40 %)
n dose given 7 (100 %)
given as mg/kg • d: n = 5 (71 %)
mean: 0.186 (±0.14) mg/kg • d
range: 0.03–0.2 mg/kg • dcontinuously s.c.
given as mg • d: n = 2 (29 %)
mean: 3.2 mg • d
s.c. or i.m.
n treatment ongoing 1 (14 %)
duration given for n = 1/1 (100 %)
mean duration: 12 months
n off medication 3 (43 %)
duration given for n = 3/3 (100 %)
mean duration: 43 months
n switched to other therapy 2 (29 %)
re-pancreatectomy: 1/2 (50 %)
diet : 1/2 (50 %)
n dead 1 (14 %)
aDiet frequent feeding, glucose enriched meals (dextrin, tapioca starch, ricepap), gastrostomy feeding, °VPM two patients with adult-onset nesidioblastosis
DZX diazoxide, STA somatostatin analogue, CCA calcium channel antagonists, GLC glucagon, OCT octreotide, LRT lanreotide (long-acting release octreotide), NIF
nifedipine, VPM verapamil, AML amlodipine
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Table 2 Side effects in medically treated patients with CHI: overview of side effects that occurred while on therapy with one or more of the analyzed medication. Side effects
were linked to the corresponding dose that was applied. Note double entries of patients that experienced more than one side effect
Drug n treated Side effects Frequency Dose (n dose given)
DZX
mg/kg • d
DZX treated n = 644 hypertrichosis n = 170 (52 %) 11.6 (±2.9), range 5–30 (n = 132)
side effects mentioned n = 325 (50 %) fluid retention/electrolyte imbalances/edema n = 99 (30 %) 12.3 (±2.8), range 8.5–17.5 (n = 48)
vomiting/poor appetite n = 40 (12 %) 13.3 (±8.2), range 10–60 (n = 39)
bone marrow suppression n = 11 (3 %) 10.4 (±0.46), range 10–10.8 (n = 4)
heart failure n = 12 (3.7 %) 16 (±6.7), range 7.5–30 (n = 7)
anaphylactic reaction n = 3 (0.9 %) 8.5 (n = 1)
renal failure n = 2 (0.6 %) 60 (n = 1)
sinustachycardia n = 1 (0.3 %) up to 15 (n = 1)
no (major) side effects (specifically mentioned) n = 39 (12 %) 13.2 (±2.4), range 5–15 (n = 34)
STA
μg/kg • d or otherwise specified
STA treated n = 355 tachyphylaxis n = 20 (18 %) 19.5 (±7.3), range 7.1–26.3 (n = 18)
side effects mentioned n = 111 (31 %) GI-symptoms* n = 23 (21 %) 17.5 (±9.5), range 6.6–27.4 (n = 20)
(transient) impairment in growth velocity n = 15 (14 %) 17.8 (±13.5), range 7.2–55 (n = 14)
abnormal GH, IGF, IGF-BP (no growth impairment) n = 4 (3.6 %) 25.8 (±0.72), range 25–26.3 (n = 3)
necrotizing enterocolitis n = 8 (7 %) 21.5 (±4.7), range 15–27 (n = 6)
induration nodules/hematoma at injection site n = 5 (4.5 %) 120 mg • month (n = 2)
decline in weight n = 3 (2.7 %) 25 (n = 1)
asymptomatic gallstones n = 3 (2.7 %) 33.9 (±24.8), range 6.6–55 (n = 3)
cholestatic jaundice n = 1 (0.9 %) 40 (n = 1)
elevated liver enzymes n = 3 (2.7 %) 16.8 (±11.4), range 10–30 (n = 3)
anaphylactic reaction n = 1 (0.9 %) not specified
normal growth velocity (specifically mentioned) n = 52 (47 %) 19 (±8.7), range 8–55 (n = 32) 100 (±15.5) mg • month,
range 90–120 (n = 6)
GLC
mg/kg • d or otherwise specified
GLC treated n = 15 catheter obstruction n = 9 (60 %) 0.33 (±0.23), range 0.026–0.8 (n = 9)
side effects mentioned n = 15 (100 %) erythema necrolyticum migrans n = 4 (27 %) 0.3 (±0.12), range 0.22–0.46 (n = 4)
insulin autoantibodies n = 2 (13 %) 0.2 (n = 1), 1.4 mg • d (n = 1)
subcutaneous infiltrates n = 1 (7 %) 5 mg • d (n = 1)
no side effects (specifically mentioned) n = 1 (7 %) 0.21 (n = 1)
*GI-symptoms: gastrointestinal symptoms, include abdominal discomfort, fatty stock, diarrhea, unwillingness to eat; °hematoma was notified three times out of 70 i.m. injections in a total of ten patients treated with lanreotide















alone (73 %) or in combination with other drugs or
frequent feeds/specific diets (27 %). For evaluation of side
effects we included reports on short-term use of diazox-
ide, thus evaluating a total number of 644 cases of diazox-
ide application.
Hypertrichosis
The most frequent side effect was a mild to severe hyper-
trichosis, which is thought to appear dose dependent in
every patient. Of note, minoxidil, another potassium chan-
nel opener has been used as hair-regrowing treatment for
more than 20 years [15]. In the evaluated patients hyper-
trichosis was reported in only 52 % of children and
seemed to be dose-independent, e.g. it occurred in a
patient treated with a dose as low as 6 mg/kg ⋅ d [16] but
it was not present in several children treated with a dose
of 15 mg/kg ⋅ d [17]. However, this may be due to under-
reporting, as hypertrichosis is often considered to be of
minor clinical importance. In contrast, for treated patients
hypertrichosis might imply stigmatization, leading to psy-
chological distress and ultimately withdrawal of diazoxide,
which was reported for two patients [12, 18].
Theoretically, topical KATP-channel blocker, such as
tolbutamide may be able to reduce hair growth, but is
has not yet been evaluated systematically for this indica-
tion [19].
Fluid retention
Less frequently, fluid retention and electrolyte imbalances
were described without further specification (30 %).
Diazoxide is a benzothiadiazine derivate and decreases
renal sodium-, chloride- as well as bicarbonate excretion
without affecting potassium excretion leading to an
expansion of extracellular fluid volume [20–22]. This ap-
pears to be opposite to other benozothiadiazines, which
can antagonize water and sodium retention during diazox-
ide treatment [21]. Therefore, diazoxide is often combined
with hydrochlorothiazide (HCT). Given the low rate of
fluid imbalances with diazoxide, a combined treatment is
not always necessary. However, under certain conditions it
seems reasonable to start with a low dose of diazoxide and
to gradually increase the dose over the first few days of
treatment, e.g. in newborns with a high glucose infusion
rate (fluid overload) and/or cardiac risk factors. Alterna-
tively, if one whishes to start with a higher dose of diazox-
ide, a combined treatment with diazoxide and HCT can
be considered even though signs of fluid retention are not
yet present. The latter approach allows a more rapid tran-
sition to alternative treatment in case of diazoxide
unresponsiveness.
Gastrointestinal symptoms (GI-symptoms)
Gastrointestinal (GI) symptoms, such as poor appetite,
nausea and vomiting occurred in 12 % of patients.
Though not generally being severe, these can complicate
treatment in CHI especially if additional dietary treat-
ment is needed.
Severe side effects of diazoxide, i.e. heart failure
(3.7 %), renal failure and petechiae (0.6 %) or anaphyl-
actic reactions (0.9 %) and laboratory parameters of
bone marrow suppression (4 %) were rarely seen. In
many of these cases, a causal relation between diazoxide
and these side effects might be disputable.
Cardiotoxicity
Cardiotoxicity of diazoxide has been questioned by
various authors. Cardiomyopathy in CHI resembles
cardiomyopathy seen in children of diabetic mothers,
suggesting hyperinsulinemia and not diazoxide treat-
ment as the underlying cause [23, 24]. However, the
temporal relation between cessation of diazoxide treat-
ment and resolution of cardiac abnormalities despite
persistent hyperinsulinemia as described for some pa-
tients suggests a causative role of diazoxide [25]. Cardiac
failure might be indirectly caused by diazoxide through
water and salt retention and thus fluid overload [26] or
directly by inducing an increase in pulmonary blood flow
resulting in an increased right ventricular work as shown
in patients with primary pulmonary hypertension [27].
Finally, in cardiomycoytes Kir6.2 is integral in the
make-up of myocellular KATP-channels and KATP-chan-
nel malfunction has been implicated in the development
and progression of heart disease [24, 28]. Taken together,
heart failure could ultimately result from 1) hyperinsuli-
nemia itself, 2) diazoxide treatment, most probably as a
secondary complication due to fluid overload or due to a
direct hemodynamic effect on pulmonary blood flow or
3) an underlying KATP-channel mutation.
Renal failure
Two patients developed renal failure under treatment
with diazoxide (<1 %). Both suffered from oliguria with
elevated urea- or creatinin-levels and additionally devel-
oped petechiae, either generalized or as quick transient
petechial rash on the back of the feet while coagulation
profile and/or platelet count was normal [29, 30]. These
both patients had additional problems, i.e. fluid retention
and cardiac decompensation or infection. Therefore it
seems more likely that renal failure was indirectly caused
rather than being due to nephrotoxicity of diazoxide.
Anaphylactic reaction and bone marrow suppression
Anaphylactic reactions were described for three patients
(<1 %), requiring reduction of diazoxide dose from
600 mg ⋅ d to 350 mg ⋅ d in an adult patient with adult-
onset nesidioblastosis with facial flushing, edema and a
slight decrease in blood pressure from 140/78 mmHg to
120/70 mmHg [31] or cessation of diazoxide treatment
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in two patients with recurrent rash or severe anaphyl-
actic reaction (not further specified), respectively [32].
Bone marrow suppression (leucopenia, isolated neutro-
penia or thrombocytopenia) occurred in 11 patients
(3 %) with CHI and in two further patients of which one
additionally suffered from pulmonary hypertension and
heart failure, whereas in the other hyperinsulinism was
due to Münchausen syndrome by proxy [33, 34]. In
these two patients neutropenia resolved when diazoxide
was ceased. In another two patients diazoxide treatment
was ceased due to neutropenia [12, 35], in the others
outcome was not mentioned. Severe infection was not
mentioned for any patient with leucopenia suggesting
that this was not the case.
In summary, diazoxide is still the first line drug in the
treatment of hyperinsulinism. It is easy to apply and
generally well tolerated. Common side effects are usually
not severe. A causal relation between diazoxide and
severe side effects remains doubtful as there are only
very few cases reported and detailed information on the
course of treatment is limited.
Octreotide
The hypothalamic release-inhibiting hormone somatostatin
is a cyclic polypeptide that is found throughout the nervous
and gastrointestinal system. It binds to specific membrane
receptors called somatostatin receptors (SSTR1-SSTR5)
[36]. In the pancreas, somatostatin has inhibitory effects on
the release of glucagon and insulin from the pancreatic islet
cells and suppresses the incretin glucagon-like-peptide 1
(GLP-1) [37]. Other actions include inhibition of gastro-
intestinal motility, gallbladder contractility and splanchnic
blood flow [38]. Early somatostatin infusion tests in infants
and children with hyperinsulinism confirmed its efficacy in
CHI [39, 40]. However, clinical use of somatostatin was re-
stricted due to its half-life of less than three minutes [36].
Therefore, various synthetic analogues of somatostatin were
tested for its efficacy in CHI [41–43]. Octreotide and lan-
reotide have a prolonged half-life of 90 minutes (octreotide)
and 23–30 days (lanreotide), respectively, when adminis-
tered by subcutaneous (s.c.) or intramuscular (i.m., lanreo-
tide) injections (FDA). Though not officially approved for
this indication it is now common to use somatostatin ana-
logues in the treatment of hyperinsulinism (off-label use).
The use of lanreotide as an alternative to octreotide pump
treatment is relatively new but has already been proven
successful in children with CHI [42, 43]. Recently, a new
somatostatin analogue preferably binding to SSTR5 (pasir-
eotide), was granted marketing for treatment of cushing’s
disease [44]. In future, pasireotide could also be of use in
the treatment of CHI.
In total, 100 patients were treated long-term with
octreotide (79 %) or lanreotide (21 %), either alone
(54 %) or in combination with other drugs or frequent
feeds/specific diets (46 %). For evaluation of side effects
we again included reports on short-term use of somato-
statin analogues (in total 355 cases).
Tachyphylaxis
An important aspect of somatostatin analogues in the
treatment of CHI is the loss of effect during prolonged
treatment (tachyphylaxis), which usually occurs within the
first days or weeks of treatment. Tachyphylaxis occurred
in a total number of 20 patients with CHI (18 %). Interest-
ingly, tachyphylaxis is generally not observed in patients
treated with octreotide for acromegaly. Several authors
propose tachyphylaxis to be caused by gastrointestinal
adaption, e.g. through tissue-specific desensitization or
down-regulation of somatostatin receptors while SSTR
expressed in pituitary tumours might have a different
turn-over rate and thus escape local adaption [36–38].
Gastrointestinal symptoms, gallstones, hepatitis
Most adverse effects such as abdominal pain or stool
abnormalities were mild and resolved spontaneously
within a few weeks under ongoing treatment. Further
gastrointestinal side effects include gallstones and necro-
tizing enterocolitis (NEC), which can be partially ex-
plained by the action profile of natural somatostatins. Of
the evaluated patients only four of them were reported
to have gallstones (3.6 %) [42, 43, 45, 46], of which three
were asymptomatic and octreotide/lanreotide treatment
was continued in combination with ursodeoxycholic
acid. However, the incidence of asymptomatic gallstones
might be higher. In acromegaly, up to 20–30 % of pa-
tients treated with octreotide develop gallstones [36]
consistent with a recent report of 28 patients with CHI
on octreotide treatment in which gallbladder pathology
was detected in 32 % of children [10]. Since the recogni-
tion or prevention of asymptomatic gallstones might
help to prevent complications, routine ultrasound once
a year or prophylactic treatment with ursodeoxycholic
acid during treatment with somatostatin analogues seems
feasible. In three patients liver enzymes increased while
on treatment with octreotide, which returned to normal
levels in all when treatment was ceased [47–49]. Interest-
ingly, in two of these, octreotide-induced hepatitis was as-
sociated with either a high dose (up to 40 μg/kg ⋅ d) or
with a gradual increase in dose from 5 to 10 μg/kg ⋅ d.
This finding stresses the importance of dose in the devel-
opment of octreotide-induced hepatitis and warrants rou-
tine examination of liver function tests particularly when
high doses are given or when dosing is increased [47].
Necrotizing enterocolitis (NEC)
The most severe side effect that is discussed to be
associated with somatostatin analogues is NEC. A causal
relation between octreotide and NEC is not yet proven,
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although the substantial reduction in splanchnic blood
flow induced by octreotide suggests a causative role [50].
Four of eight children that developed NEC while on
treatment with octreotide clearly had other risk fac-
tors for NEC: severe cardiomyopathy (n = 1) [51],
congestive heart failure due to excessive fluid over-
load (n = 2) [52, 53], and a patent ductus arteriosus
(PDA) (n = 1) [50]. Remarkably, in one of these pa-
tients the condition quickly improved upon adequate
treatment even though octreotide was increased two-
fold [50]. Severity of NEC ranged from bloody stools
to death (n = 2). Another patient additionally received
nifedipine and metoclopramide, which could as well
have contributed to the development of bowel gan-
grene [50]. Of the remaining three patients, two had
no additional extrinsic risk factors and for one patient
detailed clinical history was not provided [50]. Six of
the patients that developed NEC were full-term neo-
nates, for two patients gestational age was not given.
All children received octreotide within the first month
of life, for one child age was not given. The occur-
rence of NEC may be associated with the applied
dose, as a dose-dependent reduction in splanchnic
blood flow was shown in rats [54]. All children that
developed NEC received a dose ≥15 μg/kg ⋅ d and
the mean dose of 21.5(±4.7) μg/kg ⋅ d was remarkably
higher than the mean dose in patients without NEC
(14.9 μg/kg ⋅ d).
An additional three neonates with NEC were treated
with octreotide for other indications. One of these pa-
tients was born premature and had a PDA [55], the
other two both have had extensive cardiac surgery previ-
ous to the development of NEC with documented distal
aortic ischemia in one patient [50, 56]. An adult patient
treated with octreotide for another indication already
had pre-existing gastrointestinal symptoms with abdom-
inal distension and steatorrhoea, which worsened under
treatment with octreotide.
Taken together, in most of the cases reported octreo-
tide is merely a risk factor among others. However, all
children received octreotide within the first months of
life, all of them developed NEC within the first days or
weeks of treatment and all except one were treated with
a dose ≥15 μg/kg ⋅ d.
Growth deceleration
Since somatostatin inhibits growth hormone secretion,
treatment with somatostatin analogues might com-
promise growth velocity. Mild growth deceleration
was observed in 15 patients (13.5 %) [42, 45, 57–60].
Of these, eight patients caught up after treatment was
discontinued, dose decreased or even under ongoing
treatment. In these patients, height normalized appro-
priate for parental target height. Only five patients
(4.5 %) continued to grow below their target range
[45, 57, 59, 60]. In one patient outcome was not spe-
cified, another patient was still on treatment but
height remained only 0.6 SD below the expected
height. For 52 patients (47 %) it was particularly
mentioned that they grew normal while on long-term
treatment with somatostatin analogues. In summary,
the risk of persistent growth deceleration and in-
appropriate target height is very low. Nevertheless,
growth should be closely monitored in all patients
during and after somatostatin analogue treatment.
Calcium channel antagonists
Calcium channel antagonists such as nifedipine or
amlodipine are approved for treatment of hyperten-
sion and angina pectoris. Their use in treatment of
CHI is relatively new. They inhibit the transmembrane
influx of calcium ions into the pancreatic beta cells,
known to be an essential trigger for insulin secretion
[11]. However, most hyperinsulinism centers do not
consider these drugs as indicated because of the lack
of effectiveness. Therefore, in the treatment of CHI,
calcium channel antagonists are merely used as a
third-line drug, e.g. as an add-on treatment, in partial
diazoxide/octreotide resistance, and/or following par-
tial pancreatectomy [16, 61, 62]. In fact, 40 % of the
evaluated patients had partial to sub-total pancreatectomy
previous to treatment with calcium channel antagonist,
compared to 3 % and 17 % of patients treated with diazox-
ide and somatostatin analogues, respectively. Possible side
effects include hypotension, peripheral edema, headache,
flushing, dizziness and nausea (FDA). In CHI, calcium
channel antagonists were well tolerated, which might be
related to the relatively low dose: mean dose was 0.72
(±0.36) mg/kg ⋅ d (range 0.1-2 mg/kg ⋅ d) in patients
treated with nifedipine and 0.1 mg/kg ⋅ d in two patients
treated with amlodipine, respectively, which is in the lower
range of the recommended dose for the treatment of
hypertension in pediatric patients (nifedipine: 0.25-3
mg/kg ⋅ d; amlodipine: 0.05-0.5 mg/kg ⋅ d) [63].
In summary, while calcium channel antagonists are
safe in the treatment of hyperinsulinism, these agents do
not seem to sufficiently restore normoglycemia and are
therefore in our opinion not indicated as first line drugs
in the treatment of CHI.
Glucagon
Glucagon is a polypeptide hormone physiologically
secreted by alpha cells of the pancreatic islets to pro-
mote hepatic glycogenolysis and gluconeogenesis and
thus directly increases blood glucose levels [6]. Ini-
tially, intravenous glucagon infusion is often used in
CHI for several days or weeks to stabilize blood glu-
cose levels, however, its long-term use is limited due
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to its short half-life and the need for parenteral
administration.
Only 7 patients were treated long-term with gluca-
gon, either continuously s.c. or by frequent injections
s.c. or i.m [64–68]. Importantly, in all but one patient
glucagon was used in combination with other drugs
or following subtotal pancreatectomy. Continuous s.c.
glucagon infusion is frequently complicated by cath-
eter obstructions occurring daily or 2–3 times per
week [65]. A stabilized formulation of glucagon was
successfully administered in three children until sur-
gery could be performed resulting in less problems
regarding catheter blockage [65]. Two of these pa-
tients and two additional patients reported by Wald
et al. developed erythema necrolyticum migrans [65,
69]. This might be explained by an increased bioavail-
ability of the stabilized formulation of glucagon and by
the relatively high dose (up to 0.22 mg/kg ⋅ d intravenous
(i.v.) and 0.26 mg/kg ⋅ d s.c.) administered in the two pa-
tients reported by Wald et al., respectively. In these four
patients glucagon was administered s.c. over periods of up
to 3.5 months (n = 3) or i.v. as short-term management of
hypoglycemia (n = 1). In all patients lesions resolved with-
out scarring. Less severe side effects included subcutane-
ous infiltrates at the site of injection (n = 1) [67] and the
development of insulin autoantibodies (n = 2), possibly
due to the amount of insulin in the glucagon preparation
(up to 0.02 %) [64, 68].
In summary, glucagon is very helpful for the treat-
ment of hypoglycemia within the first weeks of life and
it might be beneficial following pancreatectomy and as
an add-on treatment, particularly in combination with a
somatostatin analogue to replace the octreotide/lanreo-
tide-induced suppression of endogenous glucagon se-
cretion. However, long-term treatment is still limited by
the lack of a suitable preparation for continuous s.c.
infusion.
Outlook
Although there is a broad spectrum of drugs available
for children with CHI, a considerable number of patients
do not show sufficient response to existing medical
treatment. Therefore, efforts are made to provide these
patients with alternative drugs. Recently, exendin-(9–39)
a specific GLP-1 receptor antagonist was shown to ele-
vate fasting blood glucose levels in nine individuals with
KATP-CHI [70]. Furthermore, the mammalian target of
rapamycin (mTor) inhibitor sirolimus has recently been
proven successful in four infants with severe hyperinsuli-
nemic hypoglycemia unresponsive to diazoxide [71].
Another promising approach is the development of new
somatostatin analogues, such as pasireotide, with
modified binding profiles and thus possibly a stronger
inhibitory effect on insulin secretion [44].
Conclusion
Despite increasing knowledge on etiology, data available
on long-term conservative treatment of CHI are still
poor. There exists an urgent need for prospective studies
or registers to better evaluate safety and efficacy of drug
treatment in CHI. This work serves as a basis to recon-
sider treatment strategies and provides information
especially on a rough frequency and impact of rare side
effects of drugs given to patients with CHI.
Recommendations based on our analysis:
Diazoxide
 it is important to screen for signs of fluid retention;
to monitor blood gases, sodium, chloride,
bicarbonate and potassium level, in particular within
the first weeks of treatment and when glucose
infusion rate is high; when indicated
hydrochlorothiazide should be added.
 in neonates cardiac monitoring (echocardiography)
should be performed.
Somatostatin analogues
 somatostatin analogues should be avoided in
neonates, particularly if additional risk factors for
NEC are present; if not possible, an initial dose
should not be higher than 15 μg/kg d and
excessive fluid overload must be prevented, as this
may trigger the risk of NEC; treatment must
immediately be stopped once any sign of NEC is
present.
 routine abdominal ultrasound should be performed
prior to and every 12 months after initiation of
treatment; if gallstones are present ursodeoxycholic
acid should be added.
 growth curves must be monitored; dose should only
be decreased if marked growth deceleration
becomes evident, as in most of the children the
decrease in growth velocity is transient.
 liver function must be monitored, particularly if
using a high dose or when dosing is increased.
 lanreotide should not be used in neonates as severe
side effects might require immediate discontinuation
of treatment.
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